Watch those boulders!! Perhaps a Syphilis stock--the "gift" that keeps on giving.
Hopefully the Kirk-Reed-Broder triangle will make this happen. Legacy issues here really don't matter. Mucho time and $$$$ wasted on small molecules but I guess that is water (Palifosfamide?) under the bridge. Good luck
IKWT-In Kirk We Trust
I add a few here and there as cash frees up. This remains stunningly cheap. If they announce sales and/or an approved FDA trial design, SOMEBODY should notive. If not, I will buy a few more. Nothing stays mispriced forever. Either the market or a corporate transaction eventually get us to the correct valuation.
To be fair it also ran from $2 to $5 pretty quickly. I guess we'll have to wait and see what Dr. Lewis and Co. bring us in Decemeber.
No, Kirk bought a big chunk of the offering himself. You cannot blame him. Perhaps there was just to real appetite for the issue on the institutional side. That could explain the day plus delay between announcement and pricing. .
The entire space has been under distribution for weeks. Lots of little bios are down pretty substantially. Even XON(the parent and Kirk's core holding) is trading at its lowest levels of the year. It was a IPO but I think folks were unrealistic and expected news to come out immediatley.
Billionares don't typically fall on their swords. Kirk has 7 or 8 companies that he controls (all need $$$$$) and chose to write the check here. Read the Intrexon S-1; Intrexon has likely spend a fair amount of its resources in the oncology space. My bet remains that Dr. Reed has made progress o n the synthetics and Dr. Broder joined the party to help advance the biologics thru the FDA. The only legacy issue left is Pali SCLC trial. Market is expecting nothing(as am I) so ANYTHING there would be upside.
Not too surprised. Shorts were on the ropes but the day (plus) between announcing raise and pricing gave them plenty of time to adjust positions. Next question is what will data look like in Dec. I believe breast trial includes Pali. Hard to even venture a guess since we were never provided with any substantive information re: PICASSO III results.
Ha Ha . Seriously, this will turn eventually IF IF IF the story begins to get out there. We have been drifting down on light volume. Really a paucity of buyers vs. and endless stream of sellers. Hopefully the company has a solid conference call this Month and a few people start to notice the disconnect between market valuation and sales potential. Very hopeful that CEO Milby updates shareholders on both partnering and FDA trial progress (if any) .
They need to make a concerted effort to get the word out. Most of the folks with whom I discuss this do not even understand the importance of CE mark. In a few days it will be 4 months since approval. We also need to remember there was a 6 month delay in the approval so there has been time to plan the launch. Hopefully these guys give us 2013 sales.
If we assume the German/Austrian sales effort is underway and we assume company will engage FDA in trial design shortly, the logical next step is to partner U.S. trial. The obvious question for any counterparty would be underwriting cost of trial vs. cost of an outright takeover. I guess is really boils down to "the who" is on the other side of the table-a dialysis provider or a more general medical products distributer.
Hopefully the company can ink a distribution deal outside of Germany. Perhaps the Far East or Middle east would be the best bet since they would not complicate the EU landscape if they are looking to do a larger deal down the road.
Finally, what is the status of IP claim? When the heck will we see the proverbial shot across the Tauropharm bow?
Ancillary providers in Dialysis is a tough space to invest in these days . I am long CRMD (micromicromicro cap) which has an EU approved catheter lock solution. Right now nobody cares since ther designation does not help in USA. Hopefully they begin FDA discussions soon. In the States, it is very difficult to navigate between the Big Two players. The little guys need someone to let them in the door. Good luck.
I thought it was safe to dip a toe in after the last raise. Still Piranha in the water. Now we likely have to contend with Q4 tax loss selling starting mid Nov. UGHHHHHH
Kirk does not care a lick about dog breath enhancers or their sales potential. He buys things either based on IP, a strategic asset(look at FSCS), or some perceive expertise within the company(maybe ZIOP). Kirk is building a lego set of small companies which may over time support one another and ultimately benefit the parent(Intrexon). People are beginning to question the magic as evidenced by the two extremely dilutive raises recently in the aforementioned 2 stocks. I think Dr. Reed/Mr. Kirk wil change the world. The only unknown is if it will take 2 years or 10.